AI-Designed Drugs Enter Human Trials for First Time

Google DeepMind's biotech spinoff is preparing to make medical history with drugs designed entirely by artificial intelligence.

Isomorphic Labs, founded in 2021 in the UK, will soon begin human trials of medications created using AlphaFold, the revolutionary AI that won its creators a Nobel Prize for mapping protein structures. The company's president, Max Jaderberg, calls it "a very exciting moment" as they transition from understanding biology to actively creating new medicines.

The trials mark a crucial test for AI in healthcare. While AlphaFold transformed how scientists study proteins, designing safe drugs that actually work in human bodies is far more complex. Isomorphic Labs has developed IsoDDE (Iso Drug Design Engine), a tool they say is twice as accurate as previous versions.

The company isn't working alone. Partnerships with pharmaceutical giants Eli Lilly and Novartis help ensure rigorous testing and development. Their internal pipeline focuses on immunology and oncology, targeting some of medicine's toughest challenges.

What makes these AI-designed molecules special? They're engineered to be more potent than traditional drugs. Patients could take lower doses with fewer side effects and complications. "We have so much more of an understanding about how these molecules work," Jaderberg explained.

The trials are starting later than originally planned. CEO Demis Hassabis had hoped to begin by the end of 2025, but the delay reflects the careful approach needed when human lives are at stake.

Why This Inspires

This represents more than just technological achievement. Every new drug that reaches human trials carries the hopes of patients waiting for better treatments. AI's ability to understand complex protein interactions could unlock medicines that were impossible to design before.

The company's building a clinical development team with an audacious goal: solving all diseases. "It's a crazy mission," Jaderberg admitted. "But we really mean it. We say it with a straight face, because we believe this should be possible."

For patients battling cancer or autoimmune conditions, AI-designed drugs offer something precious: renewed hope that faster, smarter drug development could bring relief sooner.

The coming months will reveal whether artificial intelligence can deliver on its promise to revolutionize medicine from the lab to the patient's bedside.